Sign up now and fund within 24h to get free NKE, GPRO or DBX stock. T&Cs apply.
Redeem Now

Senseonics Holdings, Inc.

1 day chart

Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.

Sign up and fund a new Wall St account and get a full U.S. share.

T&Cs apply
Claim now
Kickstart your portfolio with a U.S. stock on us

About SENS

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.

Buy US stocks in Australia starting with SENS. Open an account and start investing today!

Market Capitalisation

$197.36M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

2.35M

High today

$0.35

Low today

$0.34

Open price

$0.34

52-week high

$0.75

52-week low

$0.32


What does Senseonics do and how does it earn money?

It's in the blood. Senseonics Holdings, Inc. is a medical technology company that develops and manufactures Continuous Glucose Monitoring (CGM) systems, aiming “to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy.” 

The company’s CGMs are an industry first. While others require weekly or fortnightly replacements, Senseonics’ CGMs can be implanted subcutaneously for much longer periods.

The company earns revenue in one business segment via three main products: 

  • Eversense CGM which can be implanted subcutaneously for 3 months 

  • Eversense XL CGM which can be implanted subcutaneously for 6 months (currently available in Europe only)

  • Eversense E3 CGM which can be implanted subcutaneously for 6 months

In August 2020, Senseonics entered a Commercialization Agreement with Ascensia, a global diabetes treatment company. Senseonics granted Ascensia exclusive rights to distribute their Eversense CGM systems worldwide.

How does Senseonics’ Eversense CGM work?

Senseonics’ CGM systems measure a diabetic’s glucose levels (aka blood sugar) via sensors inserted under the skin by a healthcare professional. 

The sensor communicates data to a smart transmitter on top of the skin. The transmitter beams data to a smartphone app for real-time diabetes monitoring and management.

Is Senseonics profitable?

No, Senseonics is not profitable at this time. 

By their own admission, the company is in “the early commercialization stages of the Eversense brand and are focused on driving awareness of our CGM systems amongst intensively managed patients and their healthcare providers.”

Revenue has see-sawed since the company went public and net income has always been negative. In fact, net income has trended deeper into the red in FY2019, FY2020 and FY2021 with minus US$116m, US$175m and US$302m, respectively.

As of the end of FY2021, the company has accumulated a total debt of US$62.7m.

Is SENS stock a buy?

Investor sentiment on SENS is mixed. Some investors consider Senseonics uninvestable due to its weak and inconsistent financials. 

Other investors anticipate a brighter future for the company due to the U.S. Food & Drug Administration’s (FDA) recent approval of the Eversense E3 CGM system in February 2022.

These investors are also anticipating widening adoption of Eversense CGMs due to the Commercialization Agreement with Ascensia.

Who owns SENS stock?

Senseonics largest shareholders are institutional including PHC Holdings Corporation (14.75%), BlackRock (6.71%), Vanguard Group (4.35%) and Steward Capital Holdings (4.1%).

President and CEO Timothy T. Goodnow holds 0.3%.

Ready to start your investing journey with Stake?

Open an account

SENS FAQs

  1. Find the right investing platform for you. To buy SENS shares in Australia, you’ll need to open an account with an investing platform that offers the security. Try Stake, you can sign up in minutes.
  2. Fund your brokerage account. Once you are set up you can deposit into your account with different payment methods.
  3. Search for SENS or Senseonics Holdings, Inc.. Find the stock by using the search function and go to the SENS page.
  4. Place an order to buy SENS. Press the ‘Buy’ button and choose an order type to place your trade. Depending on the order type, the trade will go through straight away or when a price target is hit.
  5. Monitor your portfolio. You’ve now purchased some SENS shares. Stay on top of your portfolio and monitor its performance. You may be eligible for dividends and shareholder voting rights that affect your stock.

The ticker symbol for Senseonics Holdings, Inc. is SENS.

One share of SENS is valued at $0.34 as of 02 November 2024.

As of 02 November 2024 Senseonics Holdings, Inc. has a market cap of $197.36M.

The Senseonics Holdings, Inc. 52-week high stock price is $0.75.

The Senseonics Holdings, Inc. 52-week low stock price is $0.32.

Yes, the Stake investing platform allows you to buy SENS shares and over 12,000 more stocks and ETFs across the ASX and Wall St.

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in SENS
on Stake

Buy SENS from US$3 brokerage

Invest in 9,500+ U.S. stocks and ETFs

Own a slice of SENS from only US$10 with fractional shares

Get started
Canstar award phone
SENS related stocks

Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610105505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2024 Stake. All rights reserved.